XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line...

BMC Cancer 2012 / 12 Vol. 12; Iss. 1

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

Dimitrios Pectasides, George Papaxoinis, Konstantine T Kalogeras, Anastasia G Eleftheraki, Ioannis Xanthakis, Thomas Makatsoris, Epaminondas Samantas, Ioannis Varthalitis, Pavlos Papakostas, Nikitas N
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
12
Language:
english
DOI:
10.1186/1471-2407-12-271
Date:
December, 2012
File:
PDF, 286 KB
english, 2012
Conversion to is in progress
Conversion to is failed